Related Experiment Video
Updated: Feb 25, 2026
09:57
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
3.7K
[Autoimmune encephalitis presenting with drug-resistant status epilepticus]
Mette Nissen1, Morten Blaabjerg
1blaabjerg@gmail.com.
Ugeskrift for Laeger
|August 10, 2017
Summary
Autoimmune encephalitis targeting the gamma-aminobuturic acidB (GABAB) receptor can cause severe neurological symptoms, including status epilepticus. Early treatment is crucial, even before antibody confirmation, for better outcomes in GABAB receptor encephalitis.
Area of Science:
- Neurology
- Immunology
- Oncology
Background:
- Autoimmune encephalitis involves antibodies targeting cell surface proteins.
- Antibodies against the gamma-aminobuturic acidB (GABAB) receptor cause limbic encephalitis, seizures, cognitive, and behavioral changes.
- GABAB receptor encephalitis is frequently linked to lung cancers.
Observation:
- This report details a case of status epilepticus resulting from GABAB receptor encephalitis.
- The patient experienced severe, refractory seizures characteristic of this condition.
Findings:
- GABAB receptor antibodies are a significant cause of autoimmune limbic encephalitis.
- Association with small-cell lung cancer or neuroendocrine lung tumors is noted.
Implications:
- Prompt initiation of treatment in suspected autoimmune encephalitis is critical.
- Delaying treatment until antibody confirmation can lead to worse patient outcomes.
- This case highlights the importance of rapid diagnosis and intervention for GABAB receptor encephalitis.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
01:20Antiepileptic Drugs: Potassium Channel Activators
852
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
852
01:14Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
01:13Seizures: Classification
1.8K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K